Imperatives around access and accountability.
In a roundtable discussion at BioSpace, panelists note how AI can do quite some harm to patients and society in the context of drug development, emphasizing the value of process steps that are predicated on human involvement.
Listen to the third and final episode of the podcast featuring Ali Pashazadeh, Treehill Partners CEO: